Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1070 | 1047 | 1107 | 1283 | 1419 | 2768 |
Fund Return | 7.04% | 4.66% | 10.7% | 8.67% | 7.25% | 10.72% |
Place in category | 944 | 182 | 1053 | 329 | 372 | 50 |
% in Category | 67 | 11 | 78 | 29 | 41 | 9 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
NG Fund Institutional Accumulation | 127.66M | 1.86 | 10.44 | 10.56 | ||
NG Income Fund Institutional Income | 249.9K | 1.86 | 10.44 | 10.57 | ||
Global Income Fund Sterling Income | 338.08M | 1.76 | 9.82 | 9.94 | ||
Income Fund Exempt 2 Accumulation | 42.43M | 1.91 | 10.72 | 10.84 | ||
Income Fund X Accumulation | 4.4M | 2.03 | 11.55 | 11.66 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Guinness Global Equity Income Z | 6.7B | 12.21 | 11.26 | 11.88 | ||
Global Income Fund Sterling Income | 338.08M | 1.76 | 9.82 | 9.94 | ||
Income Fund Exempt 2 Accumulation | 42.43M | 1.91 | 10.72 | 10.84 | ||
Income Fund X Accumulation | 4.4M | 2.03 | 11.55 | 11.66 | ||
NG Fund Institutional Accumulation | 127.66M | 1.86 | 10.44 | 10.56 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Sanofi | FR0000120578 | 3.31 | 91.89 | +0.19% | |
CME Group | US12572Q1058 | 3.02 | 234.39 | +2.19% | |
Cisco | US17275R1023 | 2.77 | 59.59 | +1.45% | |
Dominion Energy | US25746U1097 | 2.39 | 59.12 | +1.01% | |
Gilead | US3755581036 | 2.39 | 91.35 | +0.95% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | BUY | Strong Buy | Strong Buy |
Summary | Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review